Latest studies
- CompletedPhase III
A study comparing talquetamab in combination with daratumumab or in combination with daratumumab and pomalidomide versus daratumumab in combination with pomalidomide and dexamethasone in participants with multiple myeloma that returns after treatment or is resistant to treatment
This study tests whether a new medicine called talquetamab, given alongside other cancer drugs, helps people with multiple myeloma that has returned or stopped responding to past treatments. Researchers want to see if these new combinations keep the cancer under control for longer than the current standard treatment.
Relapsed or refractory multiple myelomaIsrael - RecruitingPhase I/II
A trial looking at different treatments for neuroblastoma which has come back after initial therapy
The BEACON2 trial is testing new combinations of cancer medicines for children and young people whose neuroblastoma has returned or worsened after initial treatment. The goal is to find out which drug combinations are safest and work best to control the disease and improve future care.
Relapsed NeuroblastomaIsrael - CompletedPhase III
A randomized, open-label phase 3 study of amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in participants with KRAS/NRAS and BRAF wildtype recurrent, unresectable or metastatic colorectal cancer who have received prior chemotherapy
This clinical trial is testing a new targeted drug, amivantamab, combined with chemotherapy for people with advanced bowel cancer. Researchers want to see if this combination works better at slowing cancer growth and helping people live longer than current standard targeted treatments after their first chemotherapy has stopped working.
Recurrent, unresectable or metastatic colorectal cancerIsrael - RecruitingPHASE2, PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
This study looks at a new drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for advanced pancreatic cancer. It compares this combination to the usual treatment to see if it works better and is safe for adults.
Metastatic Pancreatic Ductal AdenocarcinomaPDACIsrael - RecruitingPHASE2, PHASE3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
This study looks at a new medicine called ponsegromab for advanced pancreatic cancer that has spread, especially when patients have lost a lot of weight and feel very tired. It aims to see if adding ponsegromab to standard chemotherapy helps more than chemotherapy alone.
CachexiaMetastatic Pancreatic Ductal AdenocarcinomaIsrael - RecruitingPhase II
Finding the best treatment for lung disease from infection with Mycobacterium abscessus
This clinical trial is testing different combinations of antibiotics to find the best way to treat lung infections caused by Mycobacterium abscessus. The goal is to discover which medicines work best to clear the bacteria while causing the fewest and least severe side effects for patients.
Mycobacterium abscessus pulmonary diseaseIsrael - RecruitingPHASE3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study is testing a new medicine, plozasiran, for people with very high triglycerides who have had pancreatitis. It will check if the medicine is safe and helps reduce the risk of future pancreatitis attacks. Participants will get either the study medicine or a dummy medicine.
Severe HypertriglyceridemiaIsrael - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaIsrael - RecruitingPHASE1, PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
This study looks at new ways to treat ovarian cancer that has come back after earlier treatments. It tests a new drug called Raludotatug deruxtecan (R-DXd) by itself or with other standard treatments, to see if it's safe and helps shrink the cancer.
Ovarian Cancer RecurrentIsrael - RecruitingPHASE2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This study is testing a new medicine called belzutifan for certain types of advanced cancers, including rare adrenal gland, gut, and kidney cancers. We want to see how well it works and if it's safe for people aged 12 and over.
Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorIsrael - RecruitingPHASE3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
This study looks at a new treatment called AAA617 for men with early-stage prostate cancer that has spread a little (oligometastatic). It compares AAA617 to careful watching, to see if it can stop the cancer from growing and help men live better for longer.
Oligometastatic Prostate Cancer (OMPC)Israel - RecruitingPhase III
Phase 3, randomised, double-blind, placebo- controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH) (ZENITH-1)
This clinical trial is testing a new injection called efimosfermin alfa for people with metabolic dysfunction-associated steatohepatitis (MASH), an inflamed fatty liver condition. Researchers want to see if monthly injections over four years can safely reduce liver fat, ease inflammation, and improve liver scarring compared to a dummy treatment.
Medical condition: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Medical condition in lay language: Metabolic Fatty Liver Inflamation Therapeutic areas: Diseases [C] - Nutritional and Metabolic Diseases [C18]Israel - RecruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active Crohn's disease
This clinical trial is testing a new combination medicine, JNJ-78934804, for moderate to severe Crohn’s disease. It combines two drugs into one injection to target gut inflammation. Researchers want to see if this two-in-one approach works better than a single medicine for people whose previous treatments have stopped working.
Crohn’s diseaseIsrael - RecruitingPHASE3
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
This study is testing a new medicine called AZD6234 for adults who are overweight or have obesity and other health issues, including some with type 2 diabetes. It aims to see if adding AZD6234 to their current weight management medicines helps them lose more weight safely.
Obesity or OverweightWeight-Related ComorbidityWith/Without Diabetes Mellitus, Type 2Israel - RecruitingPHASE1
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
This study looks at a new medicine, PF-08052667, for a type of bladder cancer that hasn't spread into the muscle. It checks if the medicine works alone or with other treatments like BCG and sasanlimab, especially for cancer that has come back.
Non-muscle Invasive Bladder CancerIsrael - Recruiting
Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation
This study looks back at information from hospitals to understand serious problems that can happen during or soon after a heart procedure called ablation for fast or extra heartbeats (VT/PVC). Researchers want to find out why these problems occur and how they were managed.
Ventricular Tachycardia (VT)Premature Ventricular ComplexesIsrael - RecruitingPHASE3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
This study looks at a new medicine for agitation in people with Alzheimer's. It aims to see if an experimental drug, given as capsules, is safe and works well over a long time for those who've been in similar studies before.
Alzheimer DiseaseAgitationIsrael - RecruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
Relapsed or Refractory Multiple MyelomaIsrael - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseIsrael - RecruitingPHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
This study is testing a new drug called Zanidatamab for people with advanced HER2-positive biliary tract cancer. It compares this new drug combined with standard treatments to standard treatments alone, to see if it's more effective and safe.
Biliary Tract CancerIsrael - RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
Colorectal NeoplasmsIsrael - Active not recruitingPHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study looks at a new drug, trastuzumab deruxtecan, for people in the UK with HER2-positive stomach or food pipe cancer. It compares this drug to standard treatments for patients whose cancer has grown despite previous therapy. The aim is to see if the new drug works better and is safe.
Gastric Cancer, AdenocarcinomaGastroesophageal Junction AdenocarcinomaIsrael - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
This study looks at a new drug, pembrolizumab, for early-stage breast cancer. It's for people with a specific type of breast cancer (ER+/HER2-). Researchers want to see if adding pembrolizumab to standard chemotherapy and hormone therapy works better than standard treatment alone.
Breast CancerIsrael - RecruitingPHASE3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, linvoseltamab, for multiple myeloma that has returned or needs re-treatment. It compares linvoseltamab to a standard three-drug combination (elotuzumab, pomalidomide, and dexamethasone) to see which works better and has fewer side effects.
Relapsed Refractory Multiple Myeloma (RRMM)Israel - RecruitingPHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
This study compares a new medicine called nemtabrutinib with existing treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. The aim is to see if the new drug is as good or better.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaIsrael - Active not recruitingPHASE3
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
This study compares a new medicine called epcoritamab with standard chemotherapy for a type of lymphoma (DLBCL) that hasn't responded to earlier treatments. It aims to see if epcoritamab is safer and more effective for patients who can't have or have already had a stem cell transplant.
Diffuse Large B-cell LymphomaIsrael - Active not recruitingPHASE3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at new treatments for a type of lung cancer where standard treatment has stopped working. It compares a drug called Dato-DXd, alone or with osimertinib, against usual chemotherapy to see which helps patients live longer without their cancer getting worse.
Metastatic Non-small Cell Lung CancerIsrael - Active not recruitingPHASE3
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
This study compares two treatments, ripretinib and sunitinib, for advanced GIST (a type of cancer) in patients who have already been treated with imatinib. It aims to see which treatment works best.
Gastrointestinal Stromal TumorsIsrael - Active not recruitingPHASE3
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
This study is comparing two ways of giving a medicine called amivantamab for advanced lung cancer. One is through a drip, and the other is a new injection under the skin. We want to see if the injection is easier and quicker for patients.
Advanced or Metastatic Non-small Cell Lung CancerIsrael - Active not recruitingPHASE1, PHASE2
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
This study is looking at a new combination of treatments for advanced bladder cancer. Doctors want to see how safe and effective a new drug, sacituzumab tirumotecan, is when given with enfortumab vedotin. It's a key step in finding better ways to treat this type of cancer.
Metastatic Urothelial CarcinomaLocally Advanced Urothelial CarcinomaIsrael - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionIsrael - Active not recruitingPHASE4
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
This study compares two treatments, Radium-223 (Xofigo) and ARPI therapy, for prostate cancer that has spread to the bones. It aims to see which is more effective and safer for men who have already tried ARPIs.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Israel - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
Non-small Cell Lung CancerIsrael - Enrolling by invitationPHASE3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study looks at a new treatment called Selatogrel for people who have recently had a heart attack and are at risk of another. It checks if taking Selatogrel when symptoms start can help prevent a second heart attack.
Acute Myocardial InfarctionIsrael - Recruiting
Pompe Disease Registry Protocol
This registry tracks people with Pompe disease globally. It helps us understand the condition better, how it changes over time, and the effects of treatments. The goal is to improve care for everyone with Pompe disease.
Glycogen Storage Disease Type IIPompe DiseaseIsrael - Active not recruitingPHASE3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
This study is looking at a new medicine called ravulizumab for adults with a kidney condition called IgAN. We want to see if it helps reduce kidney damage and improve kidney function compared to a dummy medicine.
Immunoglobulin A NephropathyIgANIsrael - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
High-Risk NeuroblastomaPatient With Insufficient Response ChemoimmunotherapyIsrael - Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
MelanomaIsrael - RecruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
Non-Small Cell Lung CancerIsrael - Active not recruitingPHASE3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
This study is for people with newly diagnosed multiple myeloma who have had a stem cell transplant. It compares a new medicine called elranatamab with a standard treatment, lenalidomide, to see which works better at keeping the cancer under control. It will last about five years.
Multiple MyelomaIsrael - Active not recruitingPHASE2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This study looks at a new drug, efgartigimod, for adults with CIDP, a nerve condition. It aims to see how safe and effective it is over a long time when given under the skin. Some participants might also try taking the drug less often.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Israel - Active not recruitingPHASE3
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
This study is testing a new medicine, ianalumab, for people with active Sjögren's syndrome. Researchers want to see if it's safe and helps improve symptoms. Participants will receive either the new medicine or a dummy medicine called a placebo.
Sjogren SyndromeIsrael - Active not recruitingPHASE3
A Study of Zigakibart in Adults With IgA Nephropathy
This study is testing a new medicine, BION-1301, for adults with IgA Nephropathy to see if it can help their kidneys. It compares the new medicine to a dummy medicine (placebo).
IgA NephropathyImmunoglobulin A NephropathyIsrael - RecruitingPHASE3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
This study looks at a new gene therapy, Surabgene Lomparvovec, for 'wet' age-related macular degeneration (nAMD). It aims to see if it's safe and effective in reducing the need for frequent eye injections and protecting vision in adults.
Neovascular Age-related Macular DegenerationIsrael - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCIsrael - RecruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
Prostate CancerIsrael - RecruitingPHASE3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study looks into a new treatment for follicular lymphoma and marginal zone lymphoma that have returned or didn't respond to previous treatments. It combines a new drug, odronextamab, with an existing one, lenalidomide, and compares it to a standard treatment.
Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)Israel - RecruitingPHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
This study looks at a new treatment called intismeran autogene, given with pembrolizumab, after surgery for non-small cell lung cancer. We want to see if this combination stops the cancer from coming back compared to pembrolizumab alone.
Carcinoma, Non-Small-Cell LungIsrael - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
Unresectable Hepatocellular CarcinomaIsrael - RecruitingPHASE2, PHASE3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
This study is testing a new drug, iza-bren, for advanced triple-negative breast cancer or ER-low, HER2-negative breast cancer. It compares iza-bren with standard chemotherapy in patients who haven't had previous treatment for advanced disease and can't receive certain immunotherapy drugs.
Breast NeoplasmsIsrael